Core Insights - The latest shareholder equity disclosures for several companies, including Ajisen (China) (00538), Zai Lab Limited (09939), Yaoshi Bang (09885), and Kwansei Holdings (01925), were reported on November 21, 2025 [1] Group 1: Shareholder Changes - Ajisen (China) saw a complete divestment by Ren Yuwen, reducing holdings from 95,000 shares to 0 shares, resulting in a holding percentage change from 0.01% to 0% [2] - Zai Lab Limited had an increase in holdings by Tong Youzhi from 52,200,300 shares to 52,500,300 shares, with a holding percentage change from 11.15% to 11.21% [2] - Another increase in Zai Lab Limited was reported for KT International, which raised its holdings from 49,700,300 shares to 50,000,300 shares, changing the holding percentage from 10.62% to 10.68% [2] - Yaoshi Bang experienced a slight increase in holdings by Chen Fei from 8,800,000 shares to 9,000,000 shares, with a holding percentage change from 1.29% to 1.32% [2] - Kwansei Holdings reported an increase in holdings by Tian Dong from 3,895,400 shares to 4,443,400 shares, changing the holding percentage from 0.96% to 1.10% [2]

Core Viewpoint - The company, Yaoshi Bang (09885.HK), announced a share buyback of 200,000 shares at a cost of HKD 1.4 million on November 20 [1] Related Events - On November 20, Yaoshi Bang (09885.HK) executed a buyback of 200,000 shares for a total expenditure of HKD 1.4 million [1] - Executive director Chen Fei increased his stake by purchasing 200,000 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 表格類別： 股票 狀態： 新提交 公司名稱： 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期： 2025年11月20日 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09885 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包 ...

Core Viewpoint - The company, Yaoshi Bang (09885), announced that executive director Chen Fei purchased a total of 200,000 shares in the open market on November 20, 2025, indicating confidence in the company's future and growth potential, as well as a long-term commitment to the company [1] Summary by Relevant Sections - **Share Purchase** - Executive director Chen Fei acquired 200,000 shares in the open market [1] - **Management Confidence** - The board of directors believes that the share purchase reflects Chen's confidence in the company's prospects and growth potential [1] - **Long-term Commitment** - The share acquisition demonstrates Chen's long-term commitment to the company [1]

Core Viewpoint - The company, Yaoshi Bang (09885), has initiated a share buyback program, indicating confidence in its long-term growth and market performance, as the current stock price is perceived to be undervalued compared to its true business potential [1] Summary by Relevant Sections - **Share Buyback Details** - The company repurchased a total of 200,000 shares on November 20, 2025, under the 2025 share buyback authorization [1] - The total amount spent on the buyback was approximately HKD 1.3972 million, excluding commissions and other expenses, with an average repurchase price of HKD 6.9859 per share [1] - **Management's Perspective** - The board believes that the current stock price does not adequately reflect the company's business prospects [1] - The share buyback plan is seen as a demonstration of confidence from the board and senior management regarding the company's long-term growth and market performance [1] - The board asserts that the buyback plan aligns with the overall best interests of the company and its shareholders [1]

Core Viewpoint - The company, Yaoshibang (09885.HK), has repurchased a total of 200,000 shares on November 20, 2025, reflecting confidence in its future growth potential and long-term commitment from its executives [1] Summary by Relevant Sections - **Share Buyback Details** - The company repurchased 200,000 shares at an approximate total cost of 1,397,180 HKD, with an average repurchase price of 6.9859 HKD per share [1] - The repurchased shares will be canceled in due course [1] - **Executive Actions** - Executive Director Chen Fei purchased a total of 200,000 shares on the open market on the same date [1] - The board views Chen Fei's share acquisition as a demonstration of confidence in the company's prospects and growth potential [1]

智通财经APP讯，药师帮(09885)发布公告，于2025年11月20日，公司根据2025年股份回购授权回购股 份。合共20万股股份已于市场回购，总回购金额约为139.72万港元(不包括佣金及其他开支)，平均回购 价为每股6.9859港元。回购股份将适时注销。 董事会认为，公司目前的股价低于其真正价值，未能充分反映其业务前景。董事会认为，股份回购计划 显示董事及公司高级管理层对公司的长期增长及市场表现充满信心。董事会亦相信，股份回购计划符合 公司及其股东的整体最佳利益。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） 股份回購 及 執行董事增持股份 此公告乃藥師幫股份有限公司（「本公司」）自願向本公司股東（「股 東」）及本公司 潛 在 投 資 者 作 出。 股份回購 茲提述本公司日期為2025年5月7日、2025年5月9日、2025年5月12日、2025年5月 13日、2025年5月14日、2025年5月15日、2025年5月16日、2025年5月19日、2025年5 月21日、2025年5月22日、2025年5月23日、2025年5月26日、2025年5月27日、2025 年6月4日、2025年6月5日、2025年6月11日、2025年6月17日、2025年6月23日、2025 年8月21日、2025年10月15日、2025年10月2 ...

Group 1 - The latest shareholder equity disclosures for four companies, including 开拓药业-B, 深圳高速公路股份, 固生堂, and 药师帮, were made on November 20, 2025 [1] - 开拓药业-B saw an increase in holdings by Tong Youzhi from 51.50 million shares to 52.20 million shares, representing an increase in ownership percentage from 11.00% to 11.15% [2] - 深圳高速公路股份 experienced a rise in holdings by 江苏云杉资本管理 from 74.75 million shares to 82.23 million shares, with ownership percentage increasing from 10.00% to 11.00% [2] Group 2 - 固生堂's Action Thrive Group Limited increased its holdings from 30.03 million shares to 30.13 million shares, with a slight increase in ownership percentage from 12.97% to 13.01% [2] - 药师帮's 陈飞 raised his holdings from 8.60 million shares to 8.80 million shares, with ownership percentage increasing from 1.26% to 1.29% [2] - 固生堂's 涂志亮 increased his holdings from 81.37 million shares to 81.48 million shares, with ownership percentage slightly rising from 35.14% to 35.19% [2]

Group 1 - The company reported a revenue growth of over 15% year-on-year for Q3 2025, exceeding market expectations [1] - The GMV of the company's flagship business grew by over 120% in October 2025, with a 163% increase in Q3 2025 [1] - The self-owned brand business GMV saw a remarkable growth of over 350% in October 2025, with a 334.2% increase in Q3 2025 [1] Group 2 - The company has repurchased a total of 7.035 million shares since the beginning of 2025, with a total repurchase amount of 56.8546 million HKD at an average price of 8.08 HKD [2] - The company is a leader in the digital ecosystem construction of the domestic off-hospital pharmaceutical industry, with steady growth in its platform and self-operated business [2] - Revenue projections for 2025-2027 are estimated at 20.579 billion, 23.875 billion, and 27.947 billion CNY, with net profits of 153 million, 381 million, and 689 million CNY respectively [2]